Eli Lilly shares weekly forecast: Recovery supported by bullish momentum indicators

Traders Union
All News
Stocks
Eli lilly gains 5.05% this week

Highlights

Shares of Eli Lilly gained 5.05% to $1,431, reaching the upper boundary of the recent weekly trading range.
The stock remains well above key moving averages with strong bullish momentum but exhibits overbought signals and increased volatility.
Forecast for the coming week anticipates a range of $1,389 to $1,528, with a breakout above $1,449 triggering further upside and support below at $1,354.

Revenue upgrade absorbs FDA risk as GLP-1 momentum sustains bullish sentiment

Eli Lilly raised its 2026 revenue forecast by $5.5 billion last week, citing robust demand for its GLP-1 drugs, according to The Motley Fool. The company also reported annual revenue of $65.18 billion and net profit of $20.64 billion. Meanwhile, the FDA issued new vision-loss warnings for GLP-1 products including Lilly's Mounjaro and Zepbound, but the update left the stock unaffected as pointed out by IBTimes.

Overbought RSI flags correction risk as bullish momentum persists this week

On the daily chart, Eli Lilly displays a sustained move higher with a firm trend and elevated volatility of 7.01%. The RSI reads 70.77, marking the stock as overbought and signaling possible overheating and correction risk, while the MACD and ADX both indicate strong upward momentum. Immediate support is seen at $1,354, reinforced by the Ichimoku Kijun at $1,290, with resistance at $1,449. The strong price positioning above key moving averages and bullish momentum indicators point to continued upside, though the overbought RSI highlights potential for short-term pullbacks.

Further upside favored as bullish signals frame coming week’s range

Over the coming trading week, price action is expected between $1,389 and $1,528, with a very high probability of further gains and a very low probability of a decrease. The base case anticipates consolidation or further upside within the stated range, supported by underlying trend signals. A bullish break above $1,449 could see momentum accelerate toward the upper range target, while a move below $1,354 would risk a deeper pullback toward practical support at $1,290.

Parshwa Turakhiya, analyst, sees shares of Eli Lilly holding strong after a 5% gain this week, driven by solid demand for its new drugs. He notes that Eli Lilly's raised 2026 revenue forecast and robust annual results are keeping sentiment bullish, even as FDA warnings on GLP-1 drugs failed to dent momentum. On the daily chart, he observes elevated volatility at 7.01% and an overbought RSI of 70.77, signaling that the rally could pause or correct in the near term. With price action likely between $1,389 and $1,528, Turakhiya sees any breakout above $1,449 as a trigger for further upside, while a drop below $1,354 may risk deeper consolidation. "After last week’s surge and with market optimism intact, I’m watching for further upside but not chasing — sticking close to the key levels and respecting the overbought signals this week."

Earlier, analysts noted that Eli Lilly’s growth prospects were supported by clinical progress and expanding distribution partnerships, reinforcing a positive technical outlook. The renewed revenue guidance and resilient price action in the current period add further weight to this view, making the $1,449 resistance a pivotal level to monitor for potential breakout momentum in the days ahead.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.